269 related articles for article (PubMed ID: 23085463)
61. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
[TBL] [Abstract][Full Text] [Related]
62. [Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma].
Tsukada N; Shingaki S; Ikeda M; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
Rinsho Ketsueki; 2015 Jul; 56(7):895-900. PubMed ID: 26256927
[TBL] [Abstract][Full Text] [Related]
63. [Development of thalidomide analogs for the treatment of multiple myeloma (MM)].
Chou T
Nihon Rinsho; 2007 Dec; 65(12):2302-8. PubMed ID: 18069277
[TBL] [Abstract][Full Text] [Related]
64. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
Front Immunol; 2018; 9():1798. PubMed ID: 30123221
[TBL] [Abstract][Full Text] [Related]
65. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Benson DM; Bakan CE; Zhang S; Collins SM; Liang J; Srivastava S; Hofmeister CC; Efebera Y; Andre P; Romagne F; Bléry M; Bonnafous C; Zhang J; Clever D; Caligiuri MA; Farag SS
Blood; 2011 Dec; 118(24):6387-91. PubMed ID: 22031859
[TBL] [Abstract][Full Text] [Related]
66. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
De Keersmaecker B; Fostier K; Corthals J; Wilgenhof S; Heirman C; Aerts JL; Thielemans K; Schots R
Cancer Immunol Immunother; 2014 Oct; 63(10):1023-36. PubMed ID: 24947180
[TBL] [Abstract][Full Text] [Related]
67. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
68. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.
Hsu AK; Quach H; Tai T; Prince HM; Harrison SJ; Trapani JA; Smyth MJ; Neeson P; Ritchie DS
Blood; 2011 Feb; 117(5):1605-13. PubMed ID: 20978269
[TBL] [Abstract][Full Text] [Related]
69. Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
Jungkunz-Stier I; Zekl M; Stühmer T; Einsele H; Seggewiss-Bernhardt R
Leuk Lymphoma; 2014 Jan; 55(1):168-76. PubMed ID: 23573828
[TBL] [Abstract][Full Text] [Related]
70. Lenalidomide enhances anti-myeloma cellular immunity.
Luptakova K; Rosenblatt J; Glotzbecker B; Mills H; Stroopinsky D; Kufe T; Vasir B; Arnason J; Tzachanis D; Zwicker JI; Joyce RM; Levine JD; Anderson KC; Kufe D; Avigan D
Cancer Immunol Immunother; 2013 Jan; 62(1):39-49. PubMed ID: 22733396
[TBL] [Abstract][Full Text] [Related]
71. Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.
Chan AC; Neeson P; Leeansyah E; Tainton K; Quach H; Prince HM; Harrison SJ; Godfrey DI; Ritchie D; Berzins SP
Clin Exp Immunol; 2014 Jan; 175(1):49-58. PubMed ID: 24032527
[TBL] [Abstract][Full Text] [Related]
72. One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
Besson L; Charrier E; Karlin L; Allatif O; Marçais A; Rouzaire P; Belmont L; Attal M; Lombard C; Salles G; Walzer T; Viel S
Front Immunol; 2018; 9():704. PubMed ID: 29706958
[TBL] [Abstract][Full Text] [Related]
73. CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma.
Zhang L; Bi E; Hong S; Qian J; Zheng C; Wang M; Yi Q
Oncotarget; 2015 Nov; 6(34):36032-40. PubMed ID: 26447613
[TBL] [Abstract][Full Text] [Related]
74. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
Shah N; Li L; McCarty J; Kaur I; Yvon E; Shaim H; Muftuoglu M; Liu E; Orlowski RZ; Cooper L; Lee D; Parmar S; Cao K; Sobieiski C; Saliba R; Hosing C; Ahmed S; Nieto Y; Bashir Q; Patel K; Bollard C; Qazilbash M; Champlin R; Rezvani K; Shpall EJ
Br J Haematol; 2017 May; 177(3):457-466. PubMed ID: 28295190
[TBL] [Abstract][Full Text] [Related]
75. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
Zago M; Adam P; Goldschmidt H; Fend F; Kanz L; Weisel K
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e7-e11. PubMed ID: 24169269
[No Abstract] [Full Text] [Related]
76. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma.
Muthu Raja KR; Kovarova L; Hajek R
Leuk Lymphoma; 2012 Jul; 53(7):1406-8. PubMed ID: 22200079
[No Abstract] [Full Text] [Related]
77. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
Gandhi AK; Kang J; Capone L; Parton A; Wu L; Zhang LH; Mendy D; Lopez-Girona A; Tran T; Sapinoso L; Fang W; Xu S; Hampton G; Bartlett JB; Schafer P
Curr Cancer Drug Targets; 2010 Mar; 10(2):155-67. PubMed ID: 20088798
[TBL] [Abstract][Full Text] [Related]
78. A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma.
Bensinger WI; Green DJ; Burwick N; Becker PS
Bone Marrow Transplant; 2014 Apr; 49(4):492-5. PubMed ID: 24419523
[TBL] [Abstract][Full Text] [Related]
79. Role of autologous and allogeneic stem cell transplantation in myeloma.
Bensinger WI
Leukemia; 2009 Mar; 23(3):442-8. PubMed ID: 19277049
[TBL] [Abstract][Full Text] [Related]
80. Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.
Balaian E; Schuster C; Schönefeldt C; Germing U; Haase D; Tuve S; Ordemann R; Ehninger G; Bornhäuser M; Oelschlaegel U; Mohr B; von Bonin M; Platzbecker U; Wermke M
Ann Hematol; 2016 Oct; 95(11):1805-10. PubMed ID: 27510179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
